New cocktail hopes to tame tough pancreatic cancer

NCT ID NCT05026905

Ongoing Disease control Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shrinking tumors and delaying progression. About 66 participants are enrolled across multiple centers in Taiwan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, nab-paclitaxel, S-1, leucovorin, oxaliplatin
What this could lead to: If successful, this could point toward a more effective first-line treatment for metastatic pancreatic cancer, potentially extending the time patients live without the disease worsening.
What could go wrong: This is a small, early-phase trial (66 participants) testing two experimental combinations. The results may not lead to a new standard of care, and the added drugs could increase side effects without improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHASE II, OPEN-LABEL, PARALLEL 2-ARM, MULTI-CENTER

Contacts and locations

Locations

China Medical University Hospital

Taichung, 400, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 800, Taiwan
National Cheng Kung University Hospital

Tainan, 600, Taiwan
Taichung Veterans General Hospital

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.